Chimeric antigen receptor T-cell therapy (CAR-T) has shown significant promise in the treatment of blood malignancies in the ...

In the fight against cancer, chimeric antigen receptor T cell (CAR-T) therapy has achieved notable success in treating blood ...

(NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic ...

In the fight against cancer, chimeric antigen receptor T cell (CAR-T) therapy has achieved notable success in treating blood ...

In the fight against cancer, chimeric antigen receptor T cell (CAR-T) therapy has achieved notable success in treating blood cancers. However, it has been largely ineffective against solid tumors.

“In particular, tumor-associated macrophages seem to have a potent inhibitory effect on CAR-T cells. CAR-NKT seem capable to avoid the inhibitory effects of macrophages since they can directly ...

Company continues to advance an innovative pipeline of NKT cell regulators for the treatment of high-value inflammatory, fibrotic and autoimmune ...

Innate immunity represents an important arm of immune response, vital to sensing damages, pathogenic or non-pathogenic, and to repair the injury tissue. It comprehends several elements including ...

Researchers found that natural killer T (NKT) cells influence whether the response generates protective antibodies that neutralise the virus or harmful ones that could exacerbate the disease in ...